Skip to main content

Table 2 Mean UAS throughout treatment

From: Omalizumab for chronic urticaria in Latin America

Time (months)

No. of patients

Mean UAS (SD)

Baseline

26

5.6 (0.6)

1

26

3.4 (1.3)

2

13

2.7 (1.5)

3

9

2.3 (1.7)

4

6

1.3 (0.8)

5

4

2.0 (2.0)

  1. UAS urticaria activity score
Back to article page

World Allergy Organization Journal

ISSN: 1939-4551

Contact us